Anthropic's IPO Buyers Will Get Stock, But Almost No Control

Anyone who buys Anthropic stock on public markets after its IPO will hold close to zero say over most major decisions at the company, including who sits on its board. The AI lab, founded in 2021 to ensure humanity can control AI and benefit from it long-term, has built a corporate governance structure that concentrates power in a trust, its founders, and its employees — everyone, in effect, except common shareholders.

Silicon Valley has seen founder-control machines before; Elon Musk and Mark Zuckerberg both run public companies without owning most of them. But Anthropic's fixation on AI safety has produced what reads as a baroque, four-layer system that leaves public investors largely spectators.

What are the four layers of control?

A public benefit charter. Anthropic is a public benefit company — a for-profit corporation legally allowed to weigh a public mission alongside profit — with the stated goal of promoting AI safety. That status shields the board's ability to make safety decisions that aren't driven entirely by shareholder value, without being sued by angry investors.

The Long Term Benefit Trust. An independent panel, the LTBT, is meant to keep the company focused on its mission to benefit humanity. It owns a class of stock that lets it elect and remove a majority of the board — the so-called Class T directors. The trust is chaired by Neil Shah, a global health expert and former managing director at GiveWell, the nonprofit that ranks charities. Its members include former Federal Reserve chair Ben Bernanke, national security expert Richard Fontaine, and Harvard physicist Christopher Stubbs. One seat is vacant, and the existing members will choose who fills it.

The founders' super-voting stock. Anthropic's seven founders jointly own a special share class that gives a majority of them 50.1% of shareholder voting power, enough to elect three board members. Only if no founder majority exists do their shares get voted in proportion with common stockholders.

A board check on the trust. When the LTBT nominates a "Specified" one of its four directors, or removes that director without cause — that is, without alleging misconduct — the board's nominating committee can refuse to approve the move and throw the decision to company employees for a vote.

Who actually sits on the board?

President Daniela Amodei chairs the board. Its members include CEO Dario Amodei — her brother — Netflix cofounder Reed Hastings, former Microsoft and GM CFO Christopher Liddell, Novartis CEO Vas Narasimhan, and Spark Capital partner Yasmin Razavi. One board seat is vacant.

The sibling pairing at the top is notable: the president chairs the body that oversees her brother, the CEO. The mix of media, pharma, finance and venture figures signals the breadth of expertise Anthropic wants around the table.

Has anything like this been tested?

Yes — and it broke. The source points to OpenAI's so-called blip, when OpenAI's board briefly fired CEO Sam Altman over concerns he was not being candid with them. Employee loyalty to Altman forced the board to back down, reinstate him, and accept a new governance structure. Anthropic's design seems to formalize that kind of employee power: staff can overrule the LTBT on board seats if they back the board over the assembled luminaries.

The founders' front has its own fault line. Cracks in their unity could hand common shareholders more say than expected, because without a founder majority their shares fall into line with common stock.

How long does founder control last?

The founders' grip has a sunset. Ten years after the IPO, they can choose to end their control — or it ends automatically when fewer than three of them remain at the company.

The LTBT outlives that handover. It continues until 85% of common shareholders vote to end it, or until it decides to step down with the board's approval. Only if and when neither special shareholder class exists any more — as the source dryly notes, hopefully not because of an AI-driven catastrophe — do common shareholders finally get control.

For IPO buyers, the trade is blunt: a stake in one of the frontier labs' economics, with essentially no vote on its direction for at least a decade.